Mailing address: Victor Bechara de Castro E-mail: becharavic@yahoo.com.br The disease can appear on areas of damaged skin, such as tattoos, and at previous intramuscular or intravenous injection sites, for example. 1 Likewise, there are described cases in which the disease developed after a vaccination. 3 In the reported case, the injected material was a lymphocyte concentration applied intradermally.
LAI is considered a therapeutic option for patients with recurrent miscarriages and uses lymphocytes obtained from the patient's male partner or from a healthy donor. The objective is to produce blocking antibodies, which act against the rejection of the embryo to reduce the risk of miscarriage. 4 According to the literature, after the exclusion of hepatitis B and C, syphilis and HIV infection, venous blood of the donor is collected and treated with an anticoagulant (heparin). The lymphocytes are separated, washed and diluted in saline solution. The injections are applied at four to six sites on the patient's upper limb and repeated at 2-or 3-week intervals. However, the therapeutic scheme and its efficacy remain controversial. 4 It is believed that the immunotherapy functions as an antigen, with possible activation of reactive T cells, stimulating the onset of an inflammatory reaction of the damaged skin, and that this reaction is sufficiently intense to persist until the full development of the disease.
The treatment of sarcoidosis is not curative, and it alters the granulomatous process and its clinical consequences. 2 There is no strict consensus. The use of tetracyclines or hydroxychloroquine is described, though with a low level of evidence of their efficacy.
The use of systemic corticosteroid, methotrexate and thalidomide is an option for extensive and refractory cases. 1, 2 Studies on the use of anti-TNF-alpha agents are scarce. Heidelberger et al., 5 in an observational multicentric study of 46 patients with cutaneous sarcoidosis, observed good response to the use of infliximab: significant response in 24% after three months; 46% after six months; and 79% after twelve months. However, attention must be given to the possibility of recurrence after suspending medication and to the risk of adverse effects, such as infections.
The presentation of this case is justified by the rarity of sarcoidosis induced by the LAI. The association is currently uncommon; however, new cases may arise as infertile couples seek this therapeutic option. More studies are needed to clarify the physiopathogenesis of sarcoidosis resulting from immunotherapy. In addition to discontinuation of the suspected inducing agent, treatment of this clinical presentation can be achieved with infliximab, showing satisfactory response. Attention should be given to possible adverse events and to relapse after suspension of treatment. q
